SGHT vs. KMTS, INMD, BBNX, SIBN, IRMD, SSII, CBLL, EMBC, RXST, and BFLY
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Kestra Medical Technologies (KMTS), InMode (INMD), Beta Bionics (BBNX), SI-BONE (SIBN), Iradimed (IRMD), SS Innovations International (SSII), CeriBell (CBLL), Embecta (EMBC), RxSight (RXST), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.
Sight Sciences vs. Its Competitors
Kestra Medical Technologies (NASDAQ:KMTS) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Sight Sciences received 15 more outperform votes than Kestra Medical Technologies when rated by MarketBeat users. However, 71.43% of users gave Kestra Medical Technologies an outperform vote while only 28.17% of users gave Sight Sciences an outperform vote.
In the previous week, Kestra Medical Technologies had 1 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Kestra Medical Technologies and 2 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.24 beat Kestra Medical Technologies' score of -0.08 indicating that Sight Sciences is being referred to more favorably in the news media.
Kestra Medical Technologies presently has a consensus price target of $27.50, suggesting a potential upside of 57.14%. Sight Sciences has a consensus price target of $4.10, suggesting a potential downside of 3.53%. Given Kestra Medical Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kestra Medical Technologies is more favorable than Sight Sciences.
Kestra Medical Technologies has higher earnings, but lower revenue than Sight Sciences.
55.5% of Sight Sciences shares are held by institutional investors. 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Kestra Medical Technologies has a net margin of 0.00% compared to Sight Sciences' net margin of -63.24%. Kestra Medical Technologies' return on equity of 0.00% beat Sight Sciences' return on equity.
Summary
Kestra Medical Technologies beats Sight Sciences on 8 of the 13 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy SGHT Stock Free SGHT Stock Alerts